CDKN2A and neoplasm: No relationship was observed between p16/p14ARF mRNA expression and overall survival (P=0.54, log-rank test); however, patients with tumours expressing low levels of p16/p14ARF mRNA (<0.1) were found to have a significantly better event-free survival than patients with tumours expressing very high levels of p16/p14ARF mRNA (⩾0.1; P=0.046, log-rank test; Figure 3C).